

Alfacalcidol

Section

Medicines for endocrine disorders

Oral > Liquid: 2 µg per mL

Oral > Solid > capsule: 0.25 µg; 1 µg

Indications

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

Beinaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to semaglutide for

Obesity

Bromocriptine

Section

Medicines for disorders of the pituitary hormone system

Indications

Therapeutic equivalent to cabergoline for

Other specified benign neoplasm of endocrine glands

Cabergoline

Section

Medicines for disorders of the pituitary hormone system

Oral > Solid > tablet: 0.5 mg; 1 mg

Indications

Other specified benign neoplasm of endocrine glands

Calcitriol

Section

Medicines for endocrine disorders

Oral > Solid > capsule: 0.25 µg; 0.5 µg

Indications

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

Canagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to methimazole for

Thyrotoxicosis

Dapagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

Diazoxide

Section

Medicines for hypoglycaemia

Oral > Liquid: 50 mg per mL

Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

Dulaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to semaglutide for

Obesity

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

Empagliflozin

Section

Oral hypoglycaemic agents

Oral > Solid: 10 mg; 25 mg

Indications

Type 2 diabetes mellitus

Estradiol

Section

Estrogens

Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

Gonadotropin deficiency

Hypopituitarism

Turner syndrome

Exenatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to semaglutide for

Obesity

Fludrocortisone

Section

Adrenal hormones and synthetic substitutes

Oral > Liquid: 100 µg per mL

Oral > Solid > tablet: 100 µg (acetate)

Indications

Adrenocortical insufficiency

Glibenclamide

Section

Oral hypoglycaemic agents

Oral > Solid: 5 mg; 2.5 mg

Indications

Type 2 diabetes mellitus

Gliclazide

Section

Oral hypoglycaemic agents

Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

Type 2 diabetes mellitus

Glucagon

Section

Medicines for hypoglycaemia

Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

Indications

Hypoglycaemia in the context of diabetes

Hydrocortisone

Section

Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 5 mg; 10 mg; 20 mg

Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule

Indications

Adrenocortical insufficiency

Insulin (analogue, long-acting)

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin (analogue, rapid-acting)

Section

Insulins

Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen

Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Insulin (human, intermediate-acting)

Section

Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin (human, short-acting)

Section

Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin analogues

Section

Insulins

Not specified

Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Insulin aspart

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 2 diabetes mellitus

Insulin degludec

Section

Insulins

Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to insulin glargine for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

Insulin detemir

Section

Insulins

Indications

Therapeutic equivalent to insulin glargine for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

Insulin glargine

Section

Insulins

Parenteral > General injections > SC: 100 units per mL

Indications

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

Insulin glulisine

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 2 diabetes mellitus

Insulin lispro

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 2 diabetes mellitus

Iodine + potassium iodide (Lugol's solution)

Section

Thyroid hormones and antithyroid medicines

Oral > Liquid: 5% w/v + 10% w/v (aqueous)

Indications

Thyrotoxicosis

Ketoconazole

Section

Medicines for endocrine disorders

Oral > Solid > tablet: 200 mg

Indications

Cushing syndrome

Levothyroxine

Section

Thyroid hormones and antithyroid medicines

Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

Indications

Hypothyroidism

Liraglutide

Section

Medicines for endocrine disorders

Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Hypoglycaemic agents

Indications

Obesity

Therapeutic equivalent to semaglutide for

Obesity

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

Medroxyprogesterone acetate

Section

Progestogens

Oral > Solid: 5 mg

Indications

Excessive menstruation with irregular cycle

Metformin

Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg (hydrochloride)

Indications

Type 2 diabetes mellitus

Methimazole

Section

Thyroid hormones and antithyroid medicines

Oral > Solid > tablet: 5 mg; 10 mg

Indications

Thyrotoxicosis

Norethisterone

Section

Progestogens

Oral > Solid: 5 mg

Indications

Excessive menstruation with irregular cycle

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

Octreotide

Section

Medicines for disorders of the pituitary hormone system

Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent

Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

Indications

Acromegaly or pituitary gigantism

Phosphorus

Section

Medicines for endocrine disorders

Oral > Other: 500 mg in sachet (elemental phosphorus) granules

Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

Hypophosphataemic rickets

Potassium iodide

Section

Thyroid hormones and antithyroid medicines

Oral > Solid > tablet: 65 mg (scored)

Indications

Thyrotoxicosis

Prednisolone

Section

Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 1 mg

Indications

Adrenocortical insufficiency

Prednisone

Section

Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 1 mg

Indications

Therapeutic equivalent to prednisolone for

Adrenocortical insufficiency

Propylthiouracil

Section

Thyroid hormones and antithyroid medicines

Oral > Solid: 50 mg

Indications

Thyrotoxicosis

Semaglutide

Section

Hypoglycaemic agents

Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution

Oral > Solid > tablet: 3 mg

Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

Indications

Obesity

Type 2 diabetes mellitus

Simvastatin

Section

Medicines for endocrine disorders

Oral > Solid: 20 mg

Indications

Polycystic ovary syndrome

Somatropin

Section

Medicines for endocrine disorders

Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge

Indications

Hypoglycaemia without associated diabetes

Testosterone

Section

Androgens

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

Indications

Testicular dysfunction or testosterone-related disorders

Tirzepatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to semaglutide for

Obesity

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

Tolbutamide

Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg

Indications

Type 2 diabetes mellitus

Zoledronic acid

Section

Medicines for endocrine disorders

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Osteogenesis imperfecta